

Form PTO-1449 FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE CITATION		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 2945-A		SERIAL NO. 09/602,351	
(Use several sheets if necessary)				APPLICANT Barbara K. Finck et al.			
				FILING DATE June 23, 2000		GROUP 1647	
U.S. PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE <small>APPROPRIATE</small>
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION <small>YES NO</small>
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
<i>DR</i>		Barker, JNWN et al., "Marked synergism between tumor necrosis factor- α and interferon- γ in regulation of keratinocyte-derived adhesion molecules and chemotactic factors," <i>J Clin Invest</i> 85:605-608, 1990.					
<i> </i>		Griffiths, CEM et al., "Modulation of leucocyte adhesion molecules, a T-cell chemotaxin (IL-8) and a regulatory cytokine (TNF- α) in allergic contact dermatitis (rhus dermatitis)," <i>Br J Dermatol</i> 124:519-526, 1991.					
<i> </i>		Groves, RW et al., "Tumour necrosis factor alpha is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expression," <i>Br J Dermatol</i> 132:345-352, 1995.					
<i> </i>		Linden, KG and Weinstein, GD, "Psoriasis: current perspectives with an emphasis on treatment," <i>Am J Med</i> 107:595-605, 1999.					
<i>DR</i>		Mease, P et al., "ENBREL® (etanercept) in patients with psoriatic arthritis and psoriasis," <i>Arthritis Rheum</i> 42 (9 Suppl):S377, 1999.					
				DATE CONSIDERED			
EXAMINER <i>Daniel Romeo 4/20/2</i>							
<small>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>							

